CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | −36,342 | $1.34 | $49K | 1,045,877 |
| 2026-08-21 | Douglas Earl Martin SVP, General Counsel | Sale | −29,697 | $2.12 | $63K | 488,267 |
| 2026-04-21 | Yoshiyama Annie SVP, Finance | Sale | −9,586 | $2.31 | $22K | 124,517 |
| 2026-03-31 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −2,867 | $2.50 | $7K | 195,338 |
| 2026-03-16 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −4,835 | $2.47 | $12K | 198,205 |
| 2026-03-16 | Chang David D President and CEO | Sale | −47,763 | $2.47 | $118K | 5,150,599 |
| 2026-03-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −7,132 | $2.60 | $19K | 203,040 |
| 2026-02-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −7,549 | $1.73 | $13K | 210,172 |
| 2026-02-02 | Chang David D President and CEO | Sale | −95,269 | $1.80 | $171K | 5,185,862 |
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | −24,001 | $1.76 | $42K | 1,252,795 |
| 2026-02-02 | Yoshiyama Annie SVP, Finance | Sale | −4,167 | $1.72 | $7K | 130,322 |
| 2026-02-02 | Roberts Zachary EVP of R&D | Sale | −35,700 | $1.77 | $63K | 581,166 |
| 2026-02-02 | Douglas Earl Martin SVP, General Counsel | Sale | −22,900 | $1.76 | $40K | 564,948 |
| 2026-01-21 | Roberts Zachary EVP of R&D | Sale | −26,269 | $1.56 | $41K | 616,866 |
| 2025-11-17 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −786 | $1.22 | $959 | 217,721 |
| 2025-10-21 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | −36,744 | $1.26 | $46K | 1,276,796 |
| 2025-06-10 | MESSEMER DEBORAH M. Director | Sale 10b5-1 | −36,885 | $1.42 | $52K | 107,431 |
| 2025-04-21 | Yoshiyama Annie SVP, Finance | Sale | −9,601 | $1.41 | $14K | 130,663 |
| 2025-03-14 | Chang David D President and CEO | Sale | −46,668 | $1.96 | $91K | 5,276,569 |
| 2025-03-14 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | −5,488 | $1.98 | $11K | 218,507 |
Page 1 of 7 · 121 trades